Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine
Authors:
- 29 June 2021
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 38 (7) , 1209-1219
Abstract
Purpose PEGylated pH-sensitive liposomes (PSL) dual-loaded with gemcitabine and curcumin were investigated for the potential application in gemcitabine-resistant pancreatic ductal adenocarcinoma (PDAC) treatment. Curcumin was employed as an inhibitor of the efflux transporter, multidrug resistance protein 5 (MRP5) in PDAC cells. Methods Liposomes were prepared with gemcitabine in the core and curcumin in the bilayers. The effects of curcumin on pH-sensitivity and ‘endosome escape’ of PSL with different PEGylation were investigated using a calcein self-quench assay. The effects of curcumin on intracellular gemcitabine concentrations, and cytotoxicity to a MIA PaCa-2 PDAC cell line was evaluated. The pharmacokinetics were investigated in rats following intravenous injection. Results The addition of curcumin to the PSL bilayers (0.2-1 mol%)slightly decreased the pH-sensitivity of PSL, but to a less extent than PEGylation (0–5 mol%). Co-treatment with curcumin increased gemcitabine cellular accumulation in a concentration-dependent manner, and resulted in synergistic cytotoxicity towards MIA PaCa-2cells.Both these effects were augmented by the use of PSL, particularly when the two drugs were co-loaded in PSL. In rats, the dual-drug loaded PSL produced significantly reduced (p < 0.05) plasma clearance (CL) and volume of distribution (Vd) for both drugs, alongside 3 to 4-fold increases in the area-under-the-concentration-time curves compared to the free drugs. Additionally, curcumin slightly increase the plasma concentrations of gemcitabine possibly also via the MRP5 inhibition effect. Conclusion Co-delivery of curcumin with gemcitabine using PSL not only increased the intracellular gemcitabine concentration thus cytotoxicity to MIA PaCa-2 cells but also significantly improved the pharmacokinetic profiles for both drugs. Graphical AbstractKeywords
Funding Information
- Marsden Fund (UOA1201)
- Auckland Medical Research Foundation (1113026)
This publication has 55 references indexed in Scilit:
- Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor TargetingJournal of Drug Delivery, 2013
- Pancreatic CancerNew England Journal of Medicine, 2010
- Gemcitabine Sensitivity Can Be Induced in Pancreatic Cancer Cells through Modulation of miR-200 and miR-21 Expression by Curcumin or Its Analogue CDFCancer Research, 2010
- Liposomal gemcitabine (GemLip)—efficient drug against hormone‐refractory Du145 and PC‐3 prostate cancer xenograftsThe Prostate, 2009
- A rapid and simple HPLC method for the determination of curcumin in rat plasma: assay development, validation and application to a pharmacokinetic study of curcumin liposomeBiomedical Chromatography, 2009
- Curcumin Inhibits the Activity of ABCG2/BCRP1, a Multidrug Resistance-Linked ABC Drug Transporter in MicePharmaceutical Research, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Preparation, Optimization, and Characterization of Topotecan Loaded PEGylated Liposomes Using Factorial DesignDrug Development and Industrial Pharmacy, 2008
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Pharmacokinetics of Pegylated Liposomal DoxorubicinClinical Pharmacokinetics, 2003